Advisory Board and Editors Cell Biology
Claire M Wells
Dr. Wells completed her PhD in 1998 from Kings College London and completed postdoctoral studies in the laboratory of Prof. Anne Ridley at University College London before returning to King's in 2003. Dr. Wells is now a Senior lecturer in the Division of Cancer Studies. She has published more than 20 papers in reputed journals serves as an editorial board member for a number of international journals and is currently associated with Cancer Research Technology’s PAK drug discovery programme.
Joëlle Wiels
Joëlle Wiels received her PhD in Genetics from Université Paris 6-Denis Diderot and then spent two years as a Post-doctoral fellow in the Division of Biochemical Oncology (Fred Hutchinson Cancer Research Center) headed by Professor Hakomori. She then moved back to France where she studied the role of glycosphingolipids in both normal and tumoral B lymphocytes. Since 1991, her main research interests include analysis of apoptotic signaling pathways and of resistance to cell death developped by B cell lymphomas. She is currently affiliated at the METSY CNRS Unit located at the Gustave Roussy Institut in Villejuif (France)
Diego Veras Wilke
Professor of physiology and pharmacology at Federal University of Ceara. Research focuses on a combination of marine natural product discovery with molecular and cellular biology to identify new anticancer leads.
Charles H Williams
Dr. Charles (Chuck) Williams is an Assistant Professor at Michigan State University, and is a basic scientist whose research centers on chemical genetics of vertebrate development and early drug discovery. His research functions at the intersection of developmental biology, chemical biology, computational biology, and personalized medicine. Dr. Williams' work includes innovative chemical biologic approaches to study embryonic development as well as developing resources to facilitate academic drug discovery.
His research has made contributions to the emerging field of chemical genetics through the discovery of chemical modulators of several key developmental pathways, including the Eggmanone, a small molecule inhibitor of the Hedgehog pathway. This work revealed novel biological insights and new therapeutic opportunities for targeting cancers downstream of the Smoothened receptor which handles the clinical problem of acquired smoothened resistance in medulloblastoma. In addition, Dr. Williams edited a book covering the latest methods and protocols in chemical biology. He has recently co-founded a start-up around a new technology for targeting glioblastoma.
Dr. Williams received a PhD in cell and developmental biology from Vanderbilt University, where he also received his BS in Molecular and Cellular Biology.
Katherine L Wilson
Katherine Wilson grew up in the Pacific Northwest (Tacoma, Washington). She earned her BS in microbiology at the University of Washington (Seattle) and her PhD in genetics at the University of California, San Francisco (UCSF), and began exploring nuclear structure as a postdoctoral fellow at UCSD. Now a professor at Johns Hopkins School of Medicine, she and her lab study the functional biochemistry and regulation of nuclear lamina proteins (emerin, lamins, BAF) to understand laminopathy disease.
Zhijin Wu
I develop statistical methodology and software for the analysis of -omics data. I am particularly interested in the regulation of transcription: the molecular mechanism as well as its association with disease.
Joseph C Wu
Joseph C. Wu, MD, PhD is Director of the Stanford Cardiovascular Institute and Simon H. Stertzer Professor of Medicine (Cardiology) and Radiology at the Stanford School of Medicine. Dr. Wu received his MD from Yale University School of Medicine. He trained in internal medicine and cardiology at UCLA followed by a PhD in the Dept of Molecular Pharmacology. His clinical interests involve cardiovascular imaging and adult congenital heart disease. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision cardiovascular medicine for prevention and treatment of patients. His lab uses a combination of genomics, stem cells, cellular & molecular biology, physiological testing, and molecular imaging technologies to better understand molecular and pathophysiological processes.
Hao Wu
Hao Wu is a patent scientist in an oncology-focused biotechnology company, Exelixis, Inc. She obtained her Ph.D. in molecular biology from Rowan University (previously known as the University of Medicine and Dentistry of New Jersey (UMDNJ) – Stratford Campus). With hands-on knowledge in various aspects of biology, including molecular biology, cell biology, biochemistry, immunology, neuroscience, oncology, Hao has worked on inventions spanning a broad range of technologies, for example, biologics, antibodies, biomarkers, diagnostics, cell therapy, gene therapy, and sequencing.
Lai-Hua Xie
Associate Professor at Rutgers-New Jersey Medical School, Editor of American Journal of Medical and Biological Research, Dataset Papers in Biology, Frontiers in Physiology, Journal of Cardiovascular Disease Research, PLOS One, World Journal Of Hypertension, and World Journal of Cardiology.
Tadashi Yamamoto
Professor of Cell Signal Unit, Okinawa Institute of Science and Technology Graduate University. Editorial Board: Genes to Cells, Molecular Biology of the Cell, Protein and Cell, Experimental & Molecular Medicine. Awarded 1987, Princess Takamatsu Cancer Research Fund Prize, 1990 Asahi Prize, 2003 NIH Fogarty Scholar-in-Residence. Former director of the Institute of Medical Science, University of Tokyo.
Dong Yan
Dong Yan received his bachelor’s degree in Biology from Nankai University (Tianjin, China) in 2001. Following an interest in neuroscience, he then joined the Institute of Neuroscience (ION), the Chinese Academy of Sciences, as a graduate student. During his graduate training, he discovered the important role of AKT local degradation in the establishment and maintenance of neuronal polarity. As a postdoctoral fellow at the University of California, San Diego, he furthered his study of neural development and disorder in vivo using the genetic model organism C. elegans. Here, he demonstrated the essential role of a conserved MAP kinase pathway, the DLK-1 pathway, in axon regeneration and synapse regulation. Dr. Yan joined the MGM department at Duke University in September 2013. His lab focuses on addressing the molecular mechanisms undying neural circuit formation during development and neurodegeneration in aging.
Guangdong Yang
Dr. Yang’s research focuses on a group of gasotransmitters, especially H2S, in the regulation of cellular functions and human diseases. Dr. Yang has received numerous awards and recognitions, including New Investigator award from the Heart and Stroke Foundation of Canada and Maureen Andrew Award from Heart and Stroke Foundation of Ontario. In his career, Dr. Yang has published ~100 peer-reviewed research articles, some of them published in high-impact journals, including as Science, Circulation, PNAS, and EMBO report etc. Their total citations are 7,481 (September 24, 2018).